Education
About Us
Working with TipRanks
Follow Us
Mochida Pharmaceutical Co., Ltd. (DE:MFY)
FRANKFURT:MFY
MFY Stock Chart & Stats
€17.10
-€0.20(-0.98%)
At close: 4:00 PM EST
€17.10
-€0.20(-0.98%)
Day’s Range― - ―
52-Week Range€16.20 - €21.40
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€698.99M
Enterprise Value€101.55B
Total Cash (Recent Filing)€54.69B
Total Debt (Recent Filing)€830.00M
Price to Earnings (P/E)19.0
Beta0.41
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding36,390,000
10 Day Avg. Volume4
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low leverage and a robust equity ratio provide durable financial flexibility, lowering refinancing and solvency risk. This strength supports sustained R&D and product launches, cushions downturns, and positions the firm to fund partnerships or M&A without pressuring cash flow over the next 2–6 months.
Healthy Profit MarginsSustained gross and net margins reflect structural cost discipline and pricing power in niche therapeutic areas. Margin durability supports reinvestment in clinical programs, steadier earnings conversion, and resilience to modest revenue setbacks, enhancing long-term operating stability.
Strong Cash Generation Relative To EarningsA strong FCF-to-net-income ratio shows efficient conversion of profits into cash, enabling consistent funding for operations, R&D and potential licensing deals. While FCF growth is volatile, the underlying cash conversion metric supports sustainable capital allocation and shareholder returns.
Bears Say
Declining Revenue GrowthA multi-year slowdown and a recent sharp revenue drop signal weakening top-line momentum that can constrain long-term earnings power. If persistent, reduced sales limit R&D funding, commercial investments, and the ability to scale new product launches, undermining future growth prospects.
Volatile Free Cash Flow GrowthVolatile FCF growth creates uncertainty in discretionary spending and capital allocation. Even with strong FCF-to-income conversion, swings in free cash flow increase risk to sustained R&D, dividends, and licensing investments, forcing conservative financial decisions during weaker periods.
Slightly Declining Return On EquityA modest decline in ROE suggests marginally weaker returns on shareholder capital which can reflect product mix shifts or pricing pressure. Persisting ROE erosion would reduce capital efficiency, constrain shareholder value creation, and signal operational headwinds in core therapeutic franchises.
Mochida Pharmaceutical Co., Ltd. News
MFY FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was €16.20 and its highest was €21.40 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is €698.99M.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 18, 2026 which is in 91 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on Feb 06, 2026. The company reported €0.377 earnings per share for the quarter, beating the consensus estimate of N/A by €0.377.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. does not currently pay dividends.
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of €0.377 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.525%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in DE:MFY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---